[go: up one dir, main page]

NO20035316L - Tiazol- eller oksazol-derivater som er anvendelige ved behandling av kardiovaskul¶re og beslektede sykdommer - Google Patents

Tiazol- eller oksazol-derivater som er anvendelige ved behandling av kardiovaskul¶re og beslektede sykdommer

Info

Publication number
NO20035316L
NO20035316L NO20035316A NO20035316A NO20035316L NO 20035316 L NO20035316 L NO 20035316L NO 20035316 A NO20035316 A NO 20035316A NO 20035316 A NO20035316 A NO 20035316A NO 20035316 L NO20035316 L NO 20035316L
Authority
NO
Norway
Prior art keywords
halogen
optionally substituted
thiazole
cardiovascular
treatment
Prior art date
Application number
NO20035316A
Other languages
English (en)
Other versions
NO20035316D0 (no
Inventor
Bernard Andre Dumaitre
Romain Luc Marie Gosmini
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20035316D0 publication Critical patent/NO20035316D0/no
Publication of NO20035316L publication Critical patent/NO20035316L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20035316A 2001-05-31 2003-11-28 Tiazol- eller oksazol-derivater som er anvendelige ved behandling av kardiovaskul¶re og beslektede sykdommer NO20035316L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0113233.1A GB0113233D0 (en) 2001-05-31 2001-05-31 Chemical compounds
PCT/EP2002/005885 WO2002096894A1 (en) 2001-05-31 2002-05-29 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases

Publications (2)

Publication Number Publication Date
NO20035316D0 NO20035316D0 (no) 2003-11-28
NO20035316L true NO20035316L (no) 2003-11-28

Family

ID=9915638

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035316A NO20035316L (no) 2001-05-31 2003-11-28 Tiazol- eller oksazol-derivater som er anvendelige ved behandling av kardiovaskul¶re og beslektede sykdommer

Country Status (21)

Country Link
US (1) US6867225B2 (no)
EP (1) EP1392665B1 (no)
JP (1) JP2004532266A (no)
KR (1) KR20040007633A (no)
CN (1) CN1529698A (no)
AT (1) ATE377007T1 (no)
AU (1) AU2002312954B2 (no)
BR (1) BR0210077A (no)
CA (1) CA2448103A1 (no)
CO (1) CO5540299A2 (no)
CZ (1) CZ20033250A3 (no)
DE (1) DE60223245T2 (no)
ES (1) ES2295352T3 (no)
GB (1) GB0113233D0 (no)
HU (1) HUP0400056A2 (no)
IL (1) IL158818A0 (no)
MX (1) MXPA03010584A (no)
NO (1) NO20035316L (no)
PL (1) PL367215A1 (no)
WO (1) WO2002096894A1 (no)
ZA (1) ZA200308864B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
AU2003264018A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
CA2497901A1 (en) 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
FR2882359A1 (fr) * 2005-02-24 2006-08-25 Negma Lerads Soc Par Actions S Derives activateurs de ppar, procede de preparation et application en therapeutique
FR2882750B1 (fr) 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
WO2007126043A1 (ja) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
FR2901792A1 (fr) * 2006-06-06 2007-12-07 Negma Lerads Soc Par Actions S DERIVES ACTIVATEURS DE PPARs, PROCEDE DE PREPARATION ET APPLICATION EN THERAPEUTIQUE
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
KR101290868B1 (ko) 2008-12-01 2013-07-29 미쓰비시 타나베 파마 코퍼레이션 티아졸환을 포함하는 카르복실산 유도체 및 그의 의약 용도
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US6207422B1 (en) * 1998-04-17 2001-03-27 The Metrohealth System Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the same
US6214620B1 (en) * 1998-09-29 2001-04-10 The Johns Hopkins University Inducible genetic suppression of cellular excitability
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
EP1345916A1 (en) * 2000-12-20 2003-09-24 Glaxo Group Limited Substituted oxazoles and thiazoles as hppar alpha agonists

Also Published As

Publication number Publication date
NO20035316D0 (no) 2003-11-28
IL158818A0 (en) 2004-05-12
ES2295352T3 (es) 2008-04-16
MXPA03010584A (es) 2004-03-09
KR20040007633A (ko) 2004-01-24
EP1392665A1 (en) 2004-03-03
CO5540299A2 (es) 2005-07-29
DE60223245D1 (de) 2007-12-13
CN1529698A (zh) 2004-09-15
BR0210077A (pt) 2004-06-22
DE60223245T2 (de) 2008-08-14
CZ20033250A3 (en) 2004-03-17
JP2004532266A (ja) 2004-10-21
CA2448103A1 (en) 2002-12-05
ATE377007T1 (de) 2007-11-15
EP1392665B1 (en) 2007-10-31
WO2002096894A1 (en) 2002-12-05
ZA200308864B (en) 2005-02-14
HUP0400056A2 (hu) 2004-04-28
US20040176427A1 (en) 2004-09-09
US6867225B2 (en) 2005-03-15
PL367215A1 (en) 2005-02-21
GB0113233D0 (en) 2001-07-25
AU2002312954B2 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
NO20035316L (no) Tiazol- eller oksazol-derivater som er anvendelige ved behandling av kardiovaskul¶re og beslektede sykdommer
TR200201473T2 (tr) Hppar alfa aktivatörleri olarak ikameli oksazol ve tiyazol türevleri
EA200600509A1 (ru) Соединения пиримидотиофена
NO20033848D0 (no) Nitrogenholdige heteroarylforbindelser med en HIV integrase inhiberende aktivitet
ATE354562T1 (de) Cyclohexylsulfon-derivate als gamma-secretase- inhibitoren
RS51471B (en) BIPHYNYLOXYXIC ACID DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES
RS20060316A (en) Derivatives of n-/heteroaryl(piperidine-2-yl)methyl/ benzamide, preparation method and application of same in therapeutics
RU2007139453A (ru) Гетеробициклические ингибиторы вируса гепатита с (hcv)
WO2005028445A3 (en) Derivatives of n-(1h-indazolyl)- and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for the treatment of pain
AR047339A1 (es) Derivados de difenilazetidona.proceso de obtencion.
DK1533292T3 (da) Dibenzylaminforbindelse og medicinsk anvendelse deraf
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
CY1109225T1 (el) ΠΑΡΑΓΩΓΑ ΜΗΛΟΝΑΜΙΔΙΟΥ ΤΑ ΟΠΟΙΑ ΠΑΡΕΜΠΟΔΙΖΟΥΝ ΤΗ ΔΡΑΣΗ ΤΗΣ γ-ΣΕΚΡΕΤΑΣΗΣ
CA2457054A1 (en) Activator of peroxisome proliferator-activated receptor .delta.
EA200401613A1 (ru) Лекарственное средство для лечения рака
EA201070782A1 (ru) Производные оксадиазола, активные в отношении сфингозин-1-фосфата(sip)
NO20063090L (no) Amidopyrazolderivater
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
CY1107206T1 (el) Παραγωγα οξαζολιου/θειαζολιου ενεργοποιητες του υποδοχεα hppar-a
NZ331613A (en) Piperazinyl or piperidinyl substituted 1,2,3,4-tetrahydronaphthalene derivatives
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
AR057558A1 (es) Compuestos de cinolincarboxamida y composicion farmaceutica
NO20071230L (no) Oksazolidinoner inneholdende oksindoler som antibakterielle midler
NO20051089L (no) Bredspektrede 2-amino-benzotiazol-sulfonamid-HIV-proteaseinhibitorer
EA200501136A1 (ru) Триазольные соединения, полезные в терапии

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application